Higher mutational events in the tumor have been correlated with greater immunogenicity and survival after checkpoint blockade treatments, e.g., ipilimumab and tremelimumab are antibodies against cytotoxic T-lymphocyte antigen 4 (CTLA-4) treatment prolonged overall survival in patients with melanoma [82,83]. Here, CTLA4 is linked to melanoma.